ASH 2023 | Polatuzumab vedotin combined with chemotherapy in untreated large B-cell lymphoma
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, speaks on the use of polatuzumab vedotin with infusional chemotherapy for untreated aggressive large B-cell lymphoma (LBCL), which is being investigated in a Phase I trial (NCT04231877). An expansion from the initial 18-patient study is ongoing, investigating the safety and efficacy of this regimen. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah, so several years ago, there was the plenary session looking at the role of polatuzumab vedotin in untreated large cell lymphoma. So this was a Phase III international study which demonstrated the superiority of polatuzumab over vincristine in untreated large cell lymphomas. However, there are subsets of patients who do receive more aggressive frontline therapies, and there had not been any studies looking at the role of polatuzumab in this setting...
Yeah, so several years ago, there was the plenary session looking at the role of polatuzumab vedotin in untreated large cell lymphoma. So this was a Phase III international study which demonstrated the superiority of polatuzumab over vincristine in untreated large cell lymphomas. However, there are subsets of patients who do receive more aggressive frontline therapies, and there had not been any studies looking at the role of polatuzumab in this setting. So this was a single arm study looking at first safety of this combination regimen. And after our initial 18 patient Phase I study and expansion is ongoing, looking at both additional safety and efficacy of this regimen. One thing we did notice was that we did not have significant issues with increasing the dose of chemotherapy of the patients with polatuzumab. One concern using polatuzumab is that it might prevent patients from receiving adequate amounts of chemotherapy. That’s not something that we saw with this study. And so far the study is ongoing and will accrue up to 50 total patients.
Read more...
Disclosures
Research Funding: Seagen Inc., Rapt, Cyteir, Incyte, Genentech, Bayer, TG Therapeutics, Merck
Consultancy: Cancer Study Group, SeaGen, Foresight Diagnostics, Abbvie
